ABVX Share Price Performance
€91.00
21.60 (31.12%)
58.6% undervalued intrinsic discount
€220.00
Fair Value
Price €91.00
Polip €220.00
Fair Value€220.00
Share Pricen/a
ABIVAX Société Anonyme Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 26 Fair Values set on narratives written by author
ABVX Community Narratives
PO
Fair Value
·Fair Value €220 58.6% undervalued intrinsic discount
OBE is best in disease
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
ABIVAX Société Anonyme
58.6% undervalued intrinsic discount
OBE is best in disease
View narrativePO
Published 3 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
PO
OBE is best in disease
Fair Value: €220 58.6% undervalued intrinsic discount
7 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ABIVAX Société Anonyme Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Sep 21, 2026
- -3.81
- 100.00%
- -6,752.03%
- 7.6%
About ABVX
- Founded
- 2013
- Employees
- 80
- CEO
- WebsiteView website
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
